Antiarrhythmic Effect of Ranolazine in Combination with Selective NCX-Inhibition in an Experimental Model of Atrial Fibrillation

Antiarrhythmic Effect of Ranolazine in Combination with Selective NCX-Inhibition in an Experimental Model of Atrial Fibrillation

The aim of this study was to investigate the effects of a combination of ranolazine with different selective inhibitors of the Na<sup>+</sup>/Ca<sup>2+</sup>-exchanger (NCX) in an established experimental model of atrial fibrillation (AF). Eighteen hearts of New Zealand white...

Full description

Bibliographic Details
Main Authors:	Julian Wolfes, Christian Ellermann, Niklas Broer, Benjamin Rath, Kevin Willy, Patrick Robert Leitz, Philipp Sebastian Lange, Lars Eckardt, Gerrit Frommeyer
Format:	Article
Language:	English
Published:	MDPI AG 2020-10-01
Series:	Pharmaceuticals
Subjects:	ranolazine NCX-inhibition atrial fibrillation Langendorff
Online Access:	https://www.mdpi.com/1424-8247/13/10/321

Similar Items

The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation
by: Fausto Devecchi, et al.
Published: (2008-08-01)

Divergent electrophysiologic action of dapagliflozin and empagliflozin on ventricular and atrial tachyarrhythmias in isolated rabbit hearts
by: Julian Wolfes, et al.
Published: (2024-02-01)

Efficacy of ranolazine in preventing atrial fibrillation following cardiac surgery: Results from a meta-analysis
by: Chintan Trivedi, MD, MPH, et al.
Published: (2017-06-01)

Role of Ranolazine in the Prevention and Treatment of Atrial Fibrillation in Patients with Left Ventricular Systolic Dysfunction: A Meta-Analysis of Randomized Clinical Trials
by: Pattranee Leelapatana, et al.
Published: (2021-04-01)

Ranolazine: Multifaceted role beyond coronary artery disease, a recent perspective
by: Gopal Chandra Ghosh, et al.
Published: (2018-01-01)

Impact of ranolazine on ventricular arrhythmias – A systematic review
by: George Bazoukis, et al.
Published: (2018-04-01)

Effects of ranolazine on various outcomes in patients with stable angina: an updated meta-analysis
by: Athanasios Manolis, et al.
Published: (2023-05-01)

Update on evidence for treatment with ranolazine in stable angina
by: Federico Carbone, et al.
Published: (2013-10-01)

Facilitation of Insulin Effects by Ranolazine in Astrocytes in Primary Culture
by: Adrián Jordá, et al.
Published: (2022-10-01)

NCX1 and NCX3: Two new effectors of delayed preconditioning in brain ischemia
by: Giuseppe Pignataro, et al.
Published: (2012-01-01)

A case of vasospastic angina. Vasospasm physiopathology: a new therapeutic role for ranolazine?
by: Carlo Uran, et al.
Published: (2020-08-01)

Improvement of Vascular Insulin Sensitivity by Ranolazine
by: Sol Guerra-Ojeda, et al.
Published: (2023-08-01)

Extended-release ranolazine: critical evaluation of its use in stable angina
by: Melloni C, et al.
Published: (2011-08-01)

RANOLAZINE IN ISCHEMIC HEART DISEASE
by: V. P. Lupanov
Published: (2015-12-01)

Computer Insight into the Molecular Level of Heart Failure. What is the Role of NCX?
by: M. Fischer, et al.
Published: (2008-01-01)

Two dimensional finite element estimation of calcium ions in presence fo NCX and Buffers in Astrocytes
by: Brajesh Kumar Jha, et al.
Published: (2018-01-01)

Pharmacokinetic study of ranolazine in Chinese healthy volunteers
by: YU Mingjie, et al.
Published: (2019-01-01)

Place of the novel drug ranolazine in the treatment of coronary artery disease
by: GA Baryshnikova, et al.
Published: (2014-12-01)

Possible Interaction between Dabigatran and Ranolazine in Patients with Renal Failure
by: Gintautas Gumbrevičius, et al.
Published: (2019-12-01)

NCX1 is a new rest target gene: Role in cerebral ischemia
by: Luigi Formisano, et al.
Published: (2013-02-01)

Ranolazine Counteracts Strength Impairment and Oxidative Stress in Aged Sarcopenic Mice
by: Alessio Torcinaro, et al.
Published: (2022-07-01)

Comparison of pharmacokinetic parameters of ranolazine between diabetic and non-diabetic rats
by: Habibeh Mashayekhi-sardoo, et al.
Published: (2022-07-01)

Single dose oral ranolazine pharmacokinetics in patients receiving maintenance hemodialysis
by: Bridget A. Scoville, et al.
Published: (2019-01-01)

Association between Ranolazine, Ischemic Preconditioning, and Cardioprotection in Patients Undergoing Scheduled Percutaneous Coronary Intervention
by: Konstantinos Kourtis, et al.
Published: (2024-01-01)

Neuroprotective effect of ranolazine improves behavioral discrepancies in a rat model of scopolamine-induced dementia
by: Shereen M. Samir, et al.
Published: (2024-01-01)

Ranolazine Attenuates Brain Inflammation in a Rat Model of Type 2 Diabetes
by: Velia Cassano, et al.
Published: (2022-12-01)

Pulmonary Vein Isolation in Obese Compared to Non-Obese Patients: Real-Life Experience from a Large Tertiary Center
by: Julian Wolfes, et al.
Published: (2022-08-01)

Exploring the Role of NCX1 and NCX3 in an In Vitro Model of Metabolism Impairment: Potential Neuroprotective Targets for Alzheimer’s Disease
by: Alessandra Preziuso, et al.
Published: (2023-07-01)

Effects of ranolazine on the arrhythmic substrate in hypertrophic cardiomyopathy
by: James A. Coleman, et al.
Published: (2024-04-01)

The Investigation of Combined Na+/Ca2+ Exchanger and the L-type Ca2+- Channel Inhibition in Langendorff-Perfused Isolated Guinea Pig Hearts
by: János PROROK, et al.
Published: (2021-09-01)

Gene Expression Profiling Elucidates Cellular Responses to NCX4040 in Human Ovarian Tumor Cells: Implications in the Mechanisms of Action of NCX4040
by: Birandra K. Sinha, et al.
Published: (2022-12-01)

Ranolazine as an additional antianginal therapy in patients with stable symptomatic coronary artery disease
by: Benjamín Sanfuentes, et al.
Published: (2018-11-01)

Effect of ranolazine on the course of ischemic heart disease after percutaneous coronary intervention
by: О.А. Yepanchintseva, et al.
Published: (2020-12-01)

Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production
by: Gennaro Riccio, et al.
Published: (2018-02-01)

Ranolazine treatment for refractory angina in a patient with Hutchinson-Gilford progeria syndrome and end stage aortic stenosis
by: Giuseppe Limongelli, et al.
Published: (2020-01-01)

NCX-DB: a unified resource for integrative analysis of the sodium calcium exchanger super-family
by: Katrin Bode, et al.
Published: (2018-04-01)

Comparison of Ranolazine and Trimetazidine on Glycemic Status in Diabetic Patients with Coronary Artery Disease – A Randomized Controlled Trial
by: Sandhiya Selvarajan, et al.
Published: (2015-01-01)

Role of Na<sup>+</sup>/Ca<sup>2+</sup> Exchanger (NCX) in Glioblastoma Cell Migration (In Vitro)
by: Federico Brandalise, et al.
Published: (2023-08-01)

Complexity of ranolazine and phenytoin use in an infant with long QT syndrome type 3
by: Reina Bianca Tan, MD, et al.
Published: (2017-01-01)

Ranolazine: A true pluripotent cardiovascular drug or jack of all trades, master of none?
by: Alice Mezincescu, et al.
Published: (2018-04-01)